BGT226 (NVP-BGT226)

Catalog No.S2749

BGT226 (NVP-BGT226) Chemical Structure

Molecular Weight(MW): 650.6

BGT226 (NVP-BGT226) is a novel class I PI3K/mTOR inhibitor for PI3Kα/β/γ with IC50 of 4 nM/63 nM/38 nM. Phase 1/2.

Size Price Stock Quantity  
In DMSO USD 700 In stock
USD 270 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

4 Customer Reviews

  • IGROV1-R10 cells were treated with BGT266(250nM) for 8 h.The effect of BGT226 on PI3K/Akt/mTOR pathway activation (A) and on expression of Mcl-1 and Bim (B).

    Cancer Lett 2014 348(1-2), 38-49. BGT226 (NVP-BGT226) purchased from Selleck.

    A. Western blot analysis of Mahlavu, SNU475 and Hep3B cell lines treated for 24 h with increasing concentrations of the drug, ranging from 0.1 to 0.5 μM. Twenty-five μg of protein were blotted to each lane. β-Actin served as a loading control. B. Analysis of Annexin-V positive cells after BGT226 treatment using the Muse™ Cell Analyzer in Mahlavu, SNU475 and Hep3B cells. The analysis was performed after 24 h of treatment with increasing concentrations of BGT226. Results are the mean of three different experiments ± SD. Asterisks indicate significant differences compared with CTRL (*p < 0.05). C. DNA staining of Mahlavu cells with the fluorescent dye DAPI is reported. In these cells, treated with increasing concentrations of the BGT226 ranging from 0.1 to 0.5 μM, aspects of nuclear chromatin condensation (arrows), representing the apoptotic mode of cell death, are observable. Bar: 10 μm.

    Oncotarget, 2015, 6(19):17147-60.. BGT226 (NVP-BGT226) purchased from Selleck.

  • Representative images of the redox ratio (1st row), NADH α1 (2nd row), and FAD α1 (third row) for SCC61 cells treated with control (1st column), cetuximab (2nd column), BGT226 (3rd column), or cisplatin (4th column). α1 quantifies the short lifetime component (α1+α2 = 1). NADH α1 represents the contribution from free NADH, while FAD α1 conversely represents the contribution from protein-bound FAD. Scale bar represents 30 um.

    PLoS One 2014 9(3), e90746. BGT226 (NVP-BGT226) purchased from Selleck.

    Western blotting analysis verifies molecular targeting of cetuximab and BGT226. Western blot for SCC61 cells. Epidermal growth factor (EGF) and transforming growth factor alpha (TGFα) activate the epidermal growth factor receptor (EGFR) and AKT pathways. Treatment with cetuximab decreases phosphorylated EGFR (pEGFR), and treatment with BGT226 decreases phosphorylated AKT (pAKT).

    PLoS One 2014 9(3), e90746. BGT226 (NVP-BGT226) purchased from Selleck.

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Description BGT226 (NVP-BGT226) is a novel class I PI3K/mTOR inhibitor for PI3Kα/β/γ with IC50 of 4 nM/63 nM/38 nM. Phase 1/2.
Targets
mTOR [1] PI3Kα [1] PI3Kγ [1] PI3Kβ [1]
4 nM 38 nM 63 nM
In vitro

The anti-proliferative and pro-apoptotic effects of NVP-BGT226 are independent of bcr-abl status. The activation of the AKT/mTOR signal cascade is suppressed by NVP-BGT226 in a concentration- and time-dependent manner. Flow cytometric analysis exhibits an accumulation of cells in the G(0)-G(1) phase with concomitant loss in the S-phase. NVP-BGT226 displays potent growth-inhibitory activity against all tested cell lines including SCC4, TU183 and KB cell lines with the IC50 ranging from 7.4 to 30.1 nM. Notably, both Detroit 562 and HONE-1 cells, which express PIK3CA mutation H1047R, are still sensitive to the growth-inhibitory effect of NVP-BGT226 treatment. In addition, the sensitivity to NVP-BGT226 between HONE-1 cells and its cisplatin-resistant variant is almost identical. Results of the terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) assay and the analysis of caspase 3/7 and PARP indicates that NVP-BGT226 induces cancer cell death through an apoptosis-independent pathway. NVP-BGT226 induces autophagy as indicated by the aggregation and upregulation of the microtubule-associated protein light chain 3B-II, and p62 degradation. Gene silencing of Beclin1 or cotreatment of the autophagosome inhibitor, 3-methyladenine, inhibits the NVP-BGT226-induced autophagy and leads to the retrieval of colony survival.[2] NVP-BGT226 inhibits growth in common myeloma cell lines and primary myeloma cells (such as NCI-H929, U266, RPMI-8226 and OPM2 MM cell lines) at nanomolar concentrations in a time-dependent and dose-dependent manner. NVP-BGT226 inhibits phosphorylation of protein kinase B (Akt), P70S6k and 4E-BP-1 in a time-dependent and dose-dependent manner. The stimulatory effect of insulin-like growth factor 1, interleukin-6 and conditioned medium of HS-5 stromal cells on myeloma cell growth is completely abrogated by NVP-BGT226. Inhibition of phosphoinositol-3-kinase/mammalian target of rapamycin by NVP-BGT226 is highly effective, and NVP-BGT226 represents a potential new candidate for targeted therapy in multiple myeloma. Combined inhibition of PI3K and mammalian target of rapamycin (mTOR) by NVP-BGT226 has been proven to be very effective in terms of induction of apoptosis and inhibition of proliferation. [3] In another study, after 24 hours, 86.9% MiaPaCa-2 100 nM NVP-BGT226 treated cells arrests at the G0/G1 phase compared to 55.6% of control cells. [4]

In vivo In a xenografted animal model, NVP-BGT226 significantly delays tumor growth in a dose-dependent manner, along with suppressed cytoplasmic expression of p-p70 S6 kinase and the presence of autophagosome formation. NVP-BGT226 inhibits tumor growth in a dose-dependent manner in a FaDu cell xenografted mouse model. Oral administration of NVP-BGT226 at 2.5 and 5 mg/kg for 3 weeks causes 34.7% and 76.1% reduction of the tumor growth on day 21, respectively (compared with control). NVP-BGT226 displays comparable inhibition against tumor growth to rapamycin. The final volume of both groups is significantly smaller than those treated with LY294002 (a PI3K inhibitor) or the control. [2]

Protocol

Cell Research:[3]
+ Expand
  • Cell lines: NCI-H929, U266, RPMI-8226 and OPM2 MM cells
  • Concentrations: 20-250 nM
  • Incubation Time: 36 hours
  • Method: NCI-H929, U266, RPMI-8226 and OPM2 MM cells are seeded in 96-well plates at a concentration of 1.5 × 104 cells/well in RPMI medium supplemented with 10% fetal bovine serum with or without NVP-BGT226 that is to be tested. After 36 hours, BrdU-labelling solution is added (final concentration: 10 μM), and cells are cultured for another 12 hours in a humidified atmosphere (37 °C/5% CO2). Then, the plates are centrifuged (10 min, 300 g), and the supernatants are discarded. The plates are dried at 60 °C for 2 hours. After fixation with ethanol/HCl for 30 min at -20 °C, the DNA is partially digested by nuclease treatment for 30 min at 37 °C. The cells are washed three times with medium and incubated with anti-BrdU-POD labelling solution for 30 min at 37 °C. The anti-POD solution is removed and the cells are washed three times with washing buffer. The ABTS substrate solution is added, and absorbance is measured in a microplate reader at 405 nm with a reference wave length of 490 nm.
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: Human FaDu xenografted mice
  • Formulation: 90% N -methyl-2-pyrrolidone (NMP)/10% PEG300
  • Dosages: 5 mg/kg for 3 weeks
  • Administration: Oral administration
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 30 mg/mL (46.11 mM)
Water slightly soluble or insoluble
Ethanol slightly soluble or insoluble
In vivo Add solvents individually and in order:
30% PEG400+0.5% Tween80+5% propylene glycol
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 650.6
Formula

C28H25F3N6O2.C4H4O4

CAS No. 1245537-68-1
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00742105 Completed Cancer|Solid Tumor|Advanced Solid Tumor Novartis Pharmaceuticals|Novartis November 2008 Phase 1
NCT00600275 Completed Solid Tumors|Breast Cancer|Cowden Syndrome Novartis Pharmaceuticals|Novartis December 2007 Phase 1|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Related PI3K Products

Tags: buy BGT226 (NVP-BGT226) | BGT226 (NVP-BGT226) supplier | purchase BGT226 (NVP-BGT226) | BGT226 (NVP-BGT226) cost | BGT226 (NVP-BGT226) manufacturer | order BGT226 (NVP-BGT226) | BGT226 (NVP-BGT226) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID